On Oct. 26, 2021, Vaxart announced that it has dosed the first subject in its Phase II COVID-19 oral tablet vaccine clinical trial, the only Phase II trial of an oral tablet COVID-19 vaccine underway in the world.

Vaxart expected to enroll 96 subjects at four sites in the U.S. in the first part of its Phase II trial. The U.S. trial was to be followed by an international trial involving a larger pool of subjects. The U.S. portion of the trial was randomized open-label dose and age escalation lead-in segment in na�ve and previously vaccinated subjects, to be followed by an international placebo-controlled efficacy trial. The full data set from the U.S. trial is expected in Q1 2022.